Clinical Trial

Monitoring Patients With Repetitive Head Impact With Gamma-glutamylcysteine Supplementation

Study acronym: RHIGSH
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to test whether the gamma - glutamylcystiene (GGC) oral supplement can reach the brain and subsequently increase antioxidant glutathione (GSH) level in people with repetitive head impact (RHI). This will reduce the oxidative stress related injury in people with RHI.This unique study's main objective is to test the: 1. Change in GSH in brain and blood levels through GGC supplementation. 2. Change in the cognitive function in RHI patients due to GGC supplementation.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2025-06-25; most recent amendment 2026-06-01.
Status change: Not Yet Recruiting → Recruiting 2025-09-02
Trial Details
NCT Number NCT07050173
Lead Sponsor Pravat Mandal
Collaborators: Chuck Noll Foundation
Conditions Repetitive Head Impacts
Enrollment 30 participants
Start Date 2026-05-01
Primary Completion 2027-11-01 (estimated)
Study Completion 2027-12-27 (estimated)
Updated on ClinicalTrials.gov 2026-06-03